EFTA Document EFTA01479583

Subject: Re: Biotech Update... [C] From: Tazia Smith ‹ > Date: Thu, 08 May 2014 14:23:51 -0400 To: jeevacation@gmail.com Cc: Nav Gupta Paul Morris Vahe Stepanian Vinit Sahni Classification: Confidential Jeffrey - Updating you on your biotech basket because most of the names are struggling to rebound from the recent rotational sell-off, exception is GILD which has good valuation support, showed a strong earnings beat, and is back up to -$79.36 (your avg cost is $79.41). FMI reported